Identification of small molecule inhibitors against UBE2C by using docking studies

Area of Science:

• Oncology
• Biochemistry
• Computational Chemistry

Background:

• Increased UBE2C (Ubiquitin-conjugating enzyme E2C) expression correlates with higher tumor grade and cancer progression.
• UBE2C is a key indicator of mitotic destruction events and is overexpressed in cervical cancer.
• Inhibiting UBE2C enhances sensitivity to radiation and chemotherapy, suggesting its potential as a drug development target.

Purpose of the Study:

• To identify potential small molecule inhibitors of UBE2C.
• To explore UBE2C as a target for novel cancer drug development.
• To computationally screen for compounds that can effectively inhibit UBE2C.

Main Methods:

• Computational modeling and docking studies were performed on UBE2C.
• Ligand libraries (ChemBank, PDB, KEGG, NCI) were docked with UBE2C using Schrodinger tools.
• Potential inhibitors were screened based on glide score, and their drug-like properties (ADME/T) were analyzed.

Main Results:

• Several compounds, including 2,4-diimino-1-methyl-1,3,5-triazepan-6-one, sulfuric acid compound with 5,6-diamino-2,4-pyrimidinediol (1:1), and 7-alpha-d-ribofuranosyl-2-aminopurine-5'-phosphate, were identified as potential UBE2C inhibitors.
• Interactions between the identified ligands and UBE2C were characterized.
• Drug-like properties of the docked compounds were assessed.

Conclusions:

• The identified compounds show promise as potential inhibitors of UBE2C.
• Further in vitro studies are warranted to validate these findings.
• These inhibitors could lead to the development of novel therapeutic strategies for cancer treatment.